PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice

  1. Taku Yoshida*,,
  2. Fang Jiang*,
  3. Tasuku Honjo*,, and
  4. Taku Okazaki*,§
  1. *Department of Immunology and Genomic Medicine,
  2. §21st Century Center of Excellence Formation, Graduate School of Medicine, Kyoto University, Yoshida-Konoe, Sakyo-ku, Kyoto, 606-8501, Japan
  1. Contributed by Tasuku Honjo, November 23, 2007 (received for review September 14, 2007)

Abstract

Although many autoimmune diseases are associated with particular HLA/H-2 haplotypes, the mechanisms through which specific HLA/H-2 haplotypes afford autoimmune susceptibility remain enigmatic. Here, we analyzed the effects of the diabetes-associated (H-2g7) and an antidiabetogenic (H-2b) H-2 haplotypes in NOD mice deficient for programmed cell death-1 (PD-1, Pdcd1), a unique model of type 1 diabetes that confers complete penetrance and rapid onset of the disease. NOD-H2 b/b Pdcd1 −/− mice were completely protected from diabetes, confirming that H-2g7 is indispensable for diabetes even in the absence of PD-1. However, NOD-H2 b/b Pdcd1 −/− mice developed autoimmune inflammation in multiple tissues including peripheral nerves, stomachs, and exocrine tissues, demonstrating that autoreactive T cells are generated in the context of H-2b. These autoreactive T cells damaged target tissues only in the absence of PD-1, confirming that PD-1 deficiency unravels the hidden autoimmune susceptibility of the strain by reducing the threshold of T cell activation. Transfer experiments revealed that CD4 T cells are the effector cells of neuritis, and nerve-infiltrating CD4 T cells are strongly deviated toward Th1. Interestingly, neuritogenic T cells were also generated in the context of H-2g7, in sharp contrast to the strict requirement of H-2g7 for diabetes. In addition, 60% of the NOD-H2 b/g7 Pdcd1 −/− mice developed diabetes, suggesting that H-2b does not dominantly suppress diabetes and that H-2g7 induces diabetes in a dose-dependent fashion.

Footnotes

  • To whom correspondence should be addressed. E-mail: honjo{at}mfour.med.kyoto-u.ac.jp
  • Author contributions: T.H. and T.O. designed research; T.Y., F.J., and T.O. performed research; T.Y. and T.O. analyzed data; and T.H. and T.O. wrote the paper.

  • Present address: Tsukuba Research Laboratories, Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635, Japan.

  • The authors declare no conflict of interest.

  • This article contains supporting information online at www.pnas.org/cgi/content/full/0710951105/DC1.

« Previous | Next Article »Table of Contents